CRA recently updated its 2011 review of health technology assessment (HTA) policies, and widened the assessment to cover 16 countries including emerging markets that have recently implemented HTA. Click the link below for a summary of key findings, with a link to the full report.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.